Dr. Sartor on Significance of Radium-223 for Community Oncologists

Oliver Sartor, MD
Published: Wednesday, Sep 16, 2015



Oliver Sartor, MD, medical oncologist, Tulane University School of Medicine, discusses key points for community oncologists regarding radium-223 for the treatment of prostate cancer.

This is the first time community oncologists will have access to an alpha particle-emitting radioactive therapeutic agent, said to be a novel concept, Sartor explains. Also, radium-223 is known as a bone-targeted agent that can prolong survival in patients with castration-resistant prostate cancer. It has yet to be determined whether it will have similar effects in other patient populations.

Radium-223 is a well-tolerated agent, Sartor says, with minimal toxicities that include diarrhea and thrombocytopenia.



Oliver Sartor, MD, medical oncologist, Tulane University School of Medicine, discusses key points for community oncologists regarding radium-223 for the treatment of prostate cancer.

This is the first time community oncologists will have access to an alpha particle-emitting radioactive therapeutic agent, said to be a novel concept, Sartor explains. Also, radium-223 is known as a bone-targeted agent that can prolong survival in patients with castration-resistant prostate cancer. It has yet to be determined whether it will have similar effects in other patient populations.

Radium-223 is a well-tolerated agent, Sartor says, with minimal toxicities that include diarrhea and thrombocytopenia.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x